Bildkälla: Stockfoto

Episurf Medical Q3’21: Continues to Build an Attractive Business - Redeye

Redeye is encouraged by the many activities carried out in the third quarter and the activities we see ahead, which are now fully financed from the recent equity issue. Furthermore, we make some minor changes to our FY21 cost estimates and believe sales in Q4 could make up for the miss in our sales estimates for Q3. Still, we argue that the case does not hinge on its sales figures at this point and that investors should look more at the longer-term prospects of the business.

Redeye is encouraged by the many activities carried out in the third quarter and the activities we see ahead, which are now fully financed from the recent equity issue. Furthermore, we make some minor changes to our FY21 cost estimates and believe sales in Q4 could make up for the miss in our sales estimates for Q3. Still, we argue that the case does not hinge on its sales figures at this point and that investors should look more at the longer-term prospects of the business.
Börsvärldens nyhetsbrev
ANNONSER